Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROMISE Trial: Optimizing GVHD Prophylaxis in Older Adults
NCT06799195Phase 2Recruiting
- Sponsor
- University of Nebraska
- Start
- Jun 2025
- Primary completion
- Apr 2031
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of cyclophosphamide in graft-versus-host disease (GVHD) (2 arms), sponsored by University of Nebraska. Primary endpoint: Functional Assessment of Cancer Therapy-Bone Marrow Transplantation at 3 months. Started Jun 2025; status: recruiting.
02
Drugs
cyclophosphamide
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT06799195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06799195.